SynthesisOrphanet journal of rare diseases2022
Systemic therapy of necrobiotic xanthogranuloma: a systematic review.
Synthesis in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Successful treatment of necrobiotic xanthogranuloma with subcutaneous immunoglobulin and topical roxulitinib.JAAD case reports · 2026Article
- Necrobiotic Xanthogranuloma (NXG): Dermoscopic and Reflectance Confocal Microscopic Findings and Review of Treatment with Intravenous Immunoglobulin (IVIG).Dermatology and therapy · 2026Article
- Lenalidomide monotherapy for necrobiotic xanthogranuloma.JAAD case reports · 2026Article
- Necrobiotic xanthogranuloma: Highlighting the role of clinicopathologic correlation in an atypical presentation.Dermatology online journal · 2026Article
- Refractory Periorbital Necrobiotic Xanthogranuloma Treated With Plasma Cell-Directed Therapy.EJHaem · 2026Article
- Periorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatment.American journal of ophthalmology case reports · 2025Article
- Plaques and Ulcers of Both Lower Limbs: A Quiz.Acta dermato-venereologica · 2025Article
- Unraveling cutaneous histiocytosis: insights into histology, pathogenesis, diagnosis, and treatment pitfalls.Frontiers in medicine · 2025Review
- A case of ulcerated nodules in association with a monoclonal gammopathy.JAAD case reports · 2024Article
- [Subsequent primary diagnosis of multiple myeloma after necrobiotic xanthogranuloma].Dermatologie (Heidelberg, Germany) · 2024Article
- Remission of necrobiotic xanthogranuloma after intravenous immunoglobulin interruption: A case report.SAGE open medical case reports · 2024Article
- Pediatric Necrobiotic Xanthogranuloma as a Novel Phenotype of IKAROS Gain of Function.Journal of clinical immunology · 2023Article
- Non-dermatologic isolated intracranial necrobiotic xanthogranuloma.BMJ case reports · 2023Article
- An unusual case of necrobiotic xanthogranuloma with IgG-λ monoclonal gammopathy presenting as cerebral manifestations.Quantitative imaging in medicine and surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEven though a plethora of systemic therapies have been proposed for necrobiotic xanthogranuloma (NXG), there is no systematic review on this topic in literature.
objectiveTo review all existing literature on the systemic therapy of NXG in order to identify the most effective therapies.
methodsAll reported papers in the literature were screened for systemic treatments of NXG. Papers without proper description of the therapies, papers describing topical therapy, and articles without assessment of effectiveness were excluded. Subsequently, we analyzed 79 papers and a total of 175 cases.
resultsThe most effective treatments for NXG are intravenous immunoglobulins (IVIG), corticosteroids, and combination therapies including corticosteroids.
conclusionsCorticosteroids and IVIG should therefore be considered first-line treatments in patients with NXG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.